AnaCardio
AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.
€62.5MSeries B
LeadNH
Novo Holdings
Activity from announced rounds
Activity in this selectionhealthworx-834921a0
Novo Holdings manages the Novo Nordisk Foundation’s investment assets and invests in healthcare and life sciences across development stages.
Investment focus
The foundation-owned holding and investment company combines a broad long-term asset portfolio with dedicated healthcare and life-sciences investment teams. Its activities include seed, venture, planetary health and principal investments.
Activity recorded by RoundOS
Recorded financing includes AnaCardio’s heart-failure drug development, Adcendo’s antibody-drug conjugates, Terremoto’s small-molecule programs and Crystalys’ gout treatment candidate. These entries show selected therapeutic investments in the database, spanning different disease areas and clinical programs.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $384M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionCrystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosedAdcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosed